European Companies Search Engine
EU funding (€18.2M): TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development Hor1 Jan 2015 EU Research and Innovation programme "Horizon"
Overview
Text
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Expressions of Interest (EoI) prior to this application and to which interested parties could respond. In total, 115 EoIs were received and ranked by the TBVI Steering Committee using proposed H2020 evaluation criteria. This led to the prioritisation of 52 R&D approaches included in this proposal. TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development. TBVAC2020 proposes to achieve this by combining creative “bottom-up” approaches for vaccine discovery (WP1), new preclinical models addressing clinical challenges (WP2) and identification and characterisation of correlates of protection (WP5) with a directive “top-down” portfolio management approach aiming to select the most promising TB vaccine candidates by their comparative evaluation using objective gating and priority setting criteria (WP6) and by supporting direct, head-to head or comparative preclinical and early clinical evaluation (WP3, WP4). This approach will both innovate and diversify the existing TB vaccine and biomarker pipeline as well as accelerate development of most promising TB vaccine candidates through early development stages. The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships (GTBVP).
Funded Companies:
| Company name | Funding amount |
| Academisch Ziekenhuis Leiden | €936,938 |
| €0.00 | |
| Aston University | €0.00 |
| €118,500 | |
| BUNDESINSTITUT für IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | €0.00 |
| Bangor University | €23,700 |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | €0.00 |
| Centre National de la Recherche Scientifique Cnrs | €1,714,513 |
| €1,416,151 | |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | €0.00 |
| FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT für TIERGESUNDHEIT | €142,200 |
| Glaxosmithkline Biologicals SA | €0.00 |
| Imperial College of Science Technology and Medicine | €308,100 |
| Institut National de la Sante et de la Recherche Medicale | €0.00 |
| Institut Pasteur | €528,980 |
| Institut Pasteur de Lille Fondation | €538,464 |
| Institut de Investigacio en Ciencies de La Salut Germans Trias i Pujol | €415,224 |
| International Tuberculosis Research Center | €0.00 |
| €218,040 | |
| Istituto Superiore DI Sanita | €206,664 |
| Kwazulu Natal Research Institute FOR TB-HIV (K-Rith) NPC | €167,227 |
| €1,194,648 | |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | €957,480 |
| Sciensano | €111,864 |
| Statens Serum Institut | €1,586,952 |
| €284,400 | |
| Stichting Biomedical Primate Research Center | €918,195 |
| €2,473,986 | |
| THE University OF Sydney | €0.00 |
| The Chancellor, Masters and Scholars of the University of Oxford | €755,643 |
| €252,687 | |
| Transgene SA | €0.00 |
| UNIVERSITAET ULM | €604,824 |
| €0.00 | |
| €0.00 | |
| €0.00 | |
| UNIVERSITE DE GENEVE | €0.00 |
| UNIVERSITE DE LAUSANNE | €0.00 |
| UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN | €220,031 |
| United Kingdom Research and Innovation | €396,294 |
| Universidad de Zaragoza | €951,792 |
| Universite Libre de Bruxelles | €218,040 |
| Universite Paul Sabatier Toulouse III | €0.00 |
| Universiteit Gent | €23,700 |
| University OF Cape Town | €355,500 |
| University of Strathclyde | €159,264 |
| €0.00 |
Source: https://cordis.europa.eu/project/id/643381
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Academisch Ziekenhuis Leiden - EU funding (€18.2M): TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
